EUVIMEDEUVIMED entdecken
Crossref

Glucagon-like peptide-1 therapies in athletes: a framework beyond weight loss

Vincenzo Maria Romeo

Academia Nutrition and Dietetics · 12.11.2026 · 3 (4)

DOI: 10.20935/acadnutr8618 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Academia Nutrition and Dietetics, online erschienen am 12.11.2026. Verfasst von Vincenzo Maria Romeo. Die Arbeit nennt 38 Literaturangaben.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Glucagon-like peptide-1 (GLP-1)–based therapies have transformed obesity treatment, but their increasing relevance to athletic populations raises questions that cannot be resolved using conventional weight management endpoints alone. In athletes, lower body weight does not necessarily imply improved body composition, health, or performance, particularly when pharmacological appetite suppression intersects with high exercise-related energy expenditure and sport-specific pressures surrounding leanness or weight. This perspective proposes an athlete-centered framework for interpreting GLP-1–based therapy across four interconnected domains: energy availability and nutritional adequacy; preservation of lean mass and functional capacity; recovery and sport-specific performance; and eating behavior, including vulnerability to dietary rigidity and disordered eating. This perspective introduces the GLP-1–Energy Availability–Performance (GEP) Framework, in which treatment effects on appetite, satiety, food reward, gastrointestinal tolerance, and dietary intake interact with training load, sport characteristics, and individual vulnerability. Rather than assuming either benefit or harm, this perspective argues that treatment success in athletes should be judged by whether clinically appropriate weight management can occur while preserving adequate fueling, lean tissue, recovery, psychological health, and sport-specific function. Direct athlete-specific evidence remains limited; accordingly, the GEP Framework should be regarded as conceptual and hypothesis-generating rather than as a validated clinical model, and its proposed pathways require prospective testing in athletic populations.

Zitieren

APA

Romeo, V. M. (2026). Glucagon-like peptide-1 therapies in athletes: a framework beyond weight loss. Academia Nutrition and Dietetics, 3(4). https://doi.org/10.20935/acadnutr8618

Vancouver

Romeo VM. Glucagon-like peptide-1 therapies in athletes: a framework beyond weight loss. Academia Nutrition and Dietetics. 2026;3(4). doi:10.20935/acadnutr8618

BibTeX
@article{Romeo2026,
  author = {Romeo, Vincenzo Maria},
  title = {Glucagon-like peptide-1 therapies in athletes: a framework beyond weight loss},
  journal = {Academia Nutrition and Dietetics},
  year = {2026},
  volume = {3},
  number = {4},
  doi = {10.20935/acadnutr8618}
}
Kostenlos starten →